Metformin and Risk of HCC in Patients With T2DM Metformin and Risk of HCC in Patients With T2DM
Is metformin use associated with a reduced risk of hepatocellular carcinoma in patients with type 2 diabetes mellitus?Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 3, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

In Older Hep B Patients, Carcinoma Surveillance Is Advised In Older Hep B Patients, Carcinoma Surveillance Is Advised
Patients older than 50 years should still be screened for hepatocellular carcinoma after the 5 years of therapy for chronic hepatitis B, new research shows.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 15, 2018 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Liver Disease Risk Factors in Patients Treated for Alcohol and Drug Dependence
Conclusion As this was only a pilot study, further data collection involving a larger, representative sample of clients should be undertaken to explore these results further. References Bennett, H. et al., 2015. Assessing the Long-Term Impact of Treating Hepatitis C Virus (HCV)-Infected People Who Inject Drugs in the UK and the Relationship between Treatment Uptake and Efficacy on Future Infections. PLoS ONE, 10(5), p.e0125846. Edeghere, O. et al., 2015. Retrospective cohort study of liver transplantation in the United Kingdom between 1994 and 2010: the impact of hepatitis C infection. Public Health, 129(5), pp.509–5...
Source: Alcohol Research UK - November 15, 2018 Category: Addiction Authors: admin Tags: Alcohol Insights Source Type: news

Metastasis in Patients With Hepatocellular Carcinoma Metastasis in Patients With Hepatocellular Carcinoma
This authors investigated the prevalence, associated factors, and prognostic impact of metastasis in hepatocellular carcinoma, proposing a modified BCLC system based on metastasis.Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 15, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Osteopontin: A new emerging role in HCV-related hepatocellular carcinoma
(Kanazawa University) A research team based in Japan led by Kanazawa University has demonstrated the effect of osteopontin on hepatitis C virus replication and interferon signaling in cancer stem cells. Their research sheds light on a novel therapeutic target for treating hepatocellular carcinoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 13, 2018 Category: Cancer & Oncology Source Type: news

FDA Approves Keytruda (pembrolizumab) for the Treatment of Patients with Hepatocellular Carcinoma (HCC) Who Have Been Previously Treated with Sorafenib
KENILWORTH, N.J.--(BUSINESS WIRE) November 9, 2018 --Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 9, 2018 Category: Drugs & Pharmacology Source Type: news

Early Development of De Novo HCC After DAA Therapy Early Development of De Novo HCC After DAA Therapy
The results of this study indicate that chronic HCV patients treated either with PegIFN or an all-oral DAA regimen remain at risk for development of de novo hepatocellular carcinoma.Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 31, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Potential markers identified for early detection and prevention of liver cancer
(Frontiers) A new study offers hope of early detection for hepatocellular carcinoma -- the second leading cause of cancer-related mortality worldwide, claiming 700,000 lives each year. The results show a dramatic increase in expression of sugar-burning 'glycolytic' genes in precancerous cirrhotic livers, associated with a significantly higher risk of developing hepatocellular carcinoma. This could lead to a biomarker which identifies those at risk of malignancy, as well as targets for new treatments. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - October 31, 2018 Category: Biology Source Type: news

Risk of HCC in NASH Compared to Other Liver Diseases Risk of HCC in NASH Compared to Other Liver Diseases
What is the pooled risk of hepatocellular carcinoma, as compared to other liver diseases, in patients with NASH with and without cirrhosis?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 24, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Updated data showed that Roche's Tecentriq in combination with Avastin shrank tumours in people with unresectable or advanced hepatocellular carcinoma (HCC)
Roche will today present updated data from a Phase Ib study evaluating Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) as a treatment for people with unresectable or advanced hepatocellular carcinoma (HCC), the most common form of liver cancer. (Source: Roche Investor Update)
Source: Roche Investor Update - October 21, 2018 Category: Pharmaceuticals Source Type: news

Sleeping beauty helps identify genes involved in a fatty liver-associated liver cancer
(Osaka University) Hepatocellular carcinoma, a deadly form of liver cancer, is increasingly being linked to non-alcoholic fatty liver disease; however, the underlying genetic mechanism of disease progression had remained unknown. Using a Sleeping Beauty mutagenesis screen, Osaka University researchers found that Sav1 and downstream components of the Hippo signaling pathway are drivers of the development of liver cancer associated with fatty liver disease. These findings pave the way for liver cancer treatments targeting the Hippo pathway. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 17, 2018 Category: Cancer & Oncology Source Type: news

Low PNI Predicts Poor Liver Cancer Outcomes
(MedPage Today) -- Meta-analysis supports prognostic tool for hepatocellular carcinoma (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - October 16, 2018 Category: Gastroenterology Source Type: news

Long-Term Aspirin Use Linked to Reduction in Liver Cancer Risk
WEDNESDAY, Oct. 10, 2018 -- Regular long-term aspirin use is associated with a dose-dependent reduction in the risk for hepatocellular carcinoma (HCC), according to a study published online Oct. 4 in JAMA Oncology. Tracey G. Simon, M.D., from... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 10, 2018 Category: Pharmaceuticals Source Type: news

Risk Factors of HCC After HBsAg Seroclearance Risk Factors of HCC After HBsAg Seroclearance
Which factors might increase risk of hepatocellular carcinoma among patients with chronic hepatitis B who have achieved seroclearance of hepatitis B surface antigen?Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 9, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Systemic Treatment of Hepatocellular Carcinoma Systemic Treatment of Hepatocellular Carcinoma
This review discusses the evolution of targeted therapy with tyrosine kinase inhibitors and recent developments in immunotherapy for systemic treatment of hepatocellular carcinoma.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 8, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Aspirin Use Tied to Reduced Risk of Liver, Ovarian Cancers
(MedPage Today) --'Strongest evidence to date'in hepatocellular carcinoma (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - October 4, 2018 Category: Gastroenterology Source Type: news

Regular Aspirin Use Curbs Risk of Liver and Ovarian Cancer Regular Aspirin Use Curbs Risk of Liver and Ovarian Cancer
Two new studies show that regular long-term aspirin use was linked to a lower risk of hepatocellular carcinoma and ovarian cancerMedscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 4, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Regular aspirin use can lower risk for ovarian, liver cancers
The regular use of aspirin was associated with a reduced risk of two deadly cancers -- ovarian and hepatocellular carcinoma. (Source: Health News - UPI.com)
Source: Health News - UPI.com - October 4, 2018 Category: Consumer Health News Source Type: news

Mass. General-led study supports aspirin's ability to reduce liver cancer risk
(Massachusetts General Hospital) The results of a study led by Massachusetts General Hospital investigators support evidence from previous studies suggesting the regular use of aspirin can reduce the risk of developing primary liver cancer -- also called hepatocellular carcinoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 4, 2018 Category: Cancer & Oncology Source Type: news

Liquid Biopsy Shows Promise for Monitoring, Detecting Liver Disease Liquid Biopsy Shows Promise for Monitoring, Detecting Liver Disease
Diseased liver cells can be detected in the peripheral blood, and those from patients with hepatocellular carcinoma (HCC) have a different gene expression profile than those from patients with chronic liver disease (CLD) but no cancer, according to new findings in Gastroenterology.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 26, 2018 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Association Between PPIs and Hepatocellular Carcinoma Association Between PPIs and Hepatocellular Carcinoma
Might long-term use of proton pump inhibitors increase the risk of hepatocellular carcinoma?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 13, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Lenvatinib for Liver Cancer Approved in Europe Lenvatinib for Liver Cancer Approved in Europe
The European Commission granted marketing authorization to lenvatinib as first-line treatment in advanced or unresectable hepatocellular carcinoma.International Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 23, 2018 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Recurrence of HCC Following Direct-acting Antiviral Therapy Recurrence of HCC Following Direct-acting Antiviral Therapy
Might direct-acting antivirals increase risk and aggressiveness of hepatocellular carcinoma recurrence? This review aimed to characterize HCC recurrence patterns after DAA therapy.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 23, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Diagnostic Value of Serum SMP30, Anti-SMP30 Antibody in HCC Diagnostic Value of Serum SMP30, Anti-SMP30 Antibody in HCC
This study evaluated the utility of anti-SMP30 antibody as a new serological marker for diagnosis of hepatocellular carcinoma.Laboratory Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 22, 2018 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

FDA Approves Lenvatinib (Lenvima) for Liver Cancer FDA Approves Lenvatinib (Lenvima) for Liver Cancer
The oral therapy lenvatinib joins sorafenib as the only drugs approved for first-line treatment of patients with unresectable hepatocellular carcinoma.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 16, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Lenvima (lenvatinib) for First-line Treatment of Unresectable Hepatocellular Carcinoma (HCC)
Woodcliff Lake, NJ and Kenilworth, NJ, Aug. 16, 2018 – Eisai Inc. and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) approved the kinase inhibitor Lenvima... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 16, 2018 Category: Drugs & Pharmacology Source Type: news

Gut-microbiome Biomarkers Identify Early Hepatocellular Carcinoma Gut-microbiome Biomarkers Identify Early Hepatocellular Carcinoma
Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - August 10, 2018 Category: Pathology Tags: Hematology-Oncology News Source Type: news

The Prevention of HBV-Related Hepatocellular Carcinoma The Prevention of HBV-Related Hepatocellular Carcinoma
This article discusses risk stratification of HBV-related hepatocellular carcinoma and summarizes three levels of preventive strategies.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 9, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Medical News Today: New drug may improve liver cancer therapy
Hepatocellular carcinoma (liver cancer) is fast growing, has poor survival rates, and has inefficient current treatments. Can they be improved? (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 6, 2018 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Direct Antiviral Therapy of Hep C May Not Boost Hepatocellular-Carcinoma Risk Direct Antiviral Therapy of Hep C May Not Boost Hepatocellular-Carcinoma Risk
Treatment of hepatitis C (HCV) with direct-acting antiviral agents does not appear to increase the risk of hepatocellular carcinoma (HCC) in individuals with cirrhosis, researchers from France report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 3, 2018 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news

Scientists develop novel drug that could potentially treat liver cancer more effectively
(National University of Singapore) A research team led by scientists from the Cancer Institute of Singapore at the National University of Singapore has developed a novel peptide drug called FFW that could potentially stop the development of hepatocellular carcinoma or primary liver cancer. This landmark discovery opens door for more effective treatment of liver cancer with less side effects. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 2, 2018 Category: Cancer & Oncology Source Type: news

America ’s Drinking Habits Are Killing More Young People, Study Suggests
Liver disease deaths are growing more common in the U.S. and disproportionately affecting younger Americans, according to a recent study. The paper, published in The BMJ just a day after a Centers for Disease Control and Prevention (CDC) report on rising liver cancer death rates, paints a troubling picture of how Americans’ drinking habits may be affecting their health. While the new study couldn’t prove causation, the researchers say drinking is likely to blame for the growing number of adults aged 24 to 35 who are dying from cirrhosis, or scarring of the liver. The researchers used deaths logged in the CDC&r...
Source: TIME: Health - July 21, 2018 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized healthytime onetime Research Source Type: news

FDA grants Breakthrough Therapy Designation for Roche's Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC)
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) as an initial (first-line) treatment for people with advanced or metastatic hepatocellular carcinoma (HCC), the most common form of liver cancer. (Source: World Pharma News)
Source: World Pharma News - July 19, 2018 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

FDA grants Breakthrough Therapy Designation for Roche ’s Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC)
Roche today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) as an initial (first-line) treatment for people with advanced or metastatic hepatocellular carcinoma (HCC), the most common form of liver cancer. (Source: Roche Media News)
Source: Roche Media News - July 18, 2018 Category: Pharmaceuticals Source Type: news

FDA grants Breakthrough Therapy Designation for Roche ’s Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC)
Roche today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) as an initial (first-line) treatment for people with advanced or metastatic hepatocellular carcinoma (HCC), the most common form of liver cancer. (Source: Roche Investor Update)
Source: Roche Investor Update - July 18, 2018 Category: Pharmaceuticals Source Type: news

Cabozantinib Improves Survival in Advanced Hepatocellular Cancer
FRIDAY, July 6, 2018 -- Cabozantinib results in significantly longer overall and progression-free survival than placebo among patients with advanced hepatocellular carcinoma, according to a study published in the July 5 issue of the New England... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 6, 2018 Category: Pharmaceuticals Source Type: news

Cabozantinib Ups Survival in Advanced Liver Cancer Cabozantinib Ups Survival in Advanced Liver Cancer
Treatment with cabozantinib improved both overall and progression-free survival in previously treated patients with advanced hepatocellular carcinoma.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 5, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

New combined treatment shows promise in hepatocellular carcinoma
(IDIBELL-Bellvitge Biomedical Research Institute) New combined treatment shows promise in Hepatocellular Carcinoma. A combination of mTOR inhibitors and Phenformin leads to an increase in overall survival. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 27, 2018 Category: Cancer & Oncology Source Type: news

Ramucirumab Improves Survival in Poor-Prognosis HCC Ramucirumab Improves Survival in Poor-Prognosis HCC
Patients with hepatocellular carcinoma who have high levels of a protein linked to a poor prognosis derive a significant survival benefit with ramucirumab, the results of a pooled analysis reveal.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 21, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Chinese Herb Prolongs Recurrence-free Survival After Curative Resection of HCC Chinese Herb Prolongs Recurrence-free Survival After Curative Resection of HCC
An aqueous extract of Poria robiniophila called Huaier granule improves recurrence-free survival (RFS) and overall survival after radical surgical resection of hepatocellular carcinoma (HCC), researchers from China report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 6, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Blueprint Medicines and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Avapritinib, BLU-554 and BLU-667 in Greater China
Combines Blueprint Medicines' Lead Clinical Programs with CStone Pharmaceutical's Regional Expertise Expands BLU-554 Development Program in Hepatocellular Carcinoma with Plans to Bring Ongoing Monotherapy Trial to China and Initiate Proof-of-Concept Com... Biopharmaceuticals, Oncology, Licensing Blueprint Medicines, CStone Pharmaceuticals, Avapritinib (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 4, 2018 Category: Pharmaceuticals Source Type: news

Lion TCR receives US$ 20 million to fund its personalized T cell therapy clinical trials against Liver cancer
SINGAPORE, May 28, 2018 -- (Healthcare Sales & Marketing Network) -- Lion TCR Pte Ltd, a clinical stage biotech pioneering T cell therapy against viral- related cancer, announced today they have raised US$ 20 million in its Series A financing round. The m... Biopharmaceuticals, Oncology, Venture Capital Lion TCR, LioCyx, T-cell, Hepatocellular carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 28, 2018 Category: Pharmaceuticals Source Type: news

International team discovers a new anti-cancer protein and it could help doctors treat liver cancer better
(Natural News) Liver cancer is on the rise, with the number of cases tripling in the U.S. since the 1980s. Around 31,000 Americans develop the disease in every year, and 24,000 people die from it. Unfortunately, patients with hepatocellular carcinoma generally have a poor overall prognosis because it’s typically diagnosed in the later stages when... (Source: NaturalNews.com)
Source: NaturalNews.com - April 30, 2018 Category: Consumer Health News Source Type: news

NCCN: Screen for Liver Cancer in Patients at Risk NCCN: Screen for Liver Cancer in Patients at Risk
Hepatocellular carcinoma is a'bad actor'with a growing death toll in the United States and Europe; when possible, patients with risk factors should be screened.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 23, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

DAA Treatment for Patients With Hepatocellular Carcinoma DAA Treatment for Patients With Hepatocellular Carcinoma
What factors need to be considered when using DAAs for HCV in patients with HCC? Review recent findings surrounding indications, efficacy and outcomes associated with DAA treatment in these patients.Current Opinion in Gastroenterology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 23, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Vitamin A derivative selectively kills liver cancer stem cells
(RIKEN) Acyclic retinoid, an artificial compound derived from vitamin A, has been found to prevent the recurrence of hepatocellular carcinoma (HCC), the most common form of liver cancer. Now, in research published in Proceedings of the National Academy of Sciences, scientists have discovered that the compound targets one class of cancer stem cells, preventing them from giving rise to new tumors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 23, 2018 Category: Cancer & Oncology Source Type: news

Immunotherapy Prolongs Hepatocellular Carcinoma Survival Immunotherapy Prolongs Hepatocellular Carcinoma Survival
The benefits of immunotherapy with cytokine-induced killer cells continue to be seen in a follow-up extension study of patients with hepatocellular carcinoma.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 18, 2018 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Selective internal radiation therapy (SIRT) fails to extend survival in the SORAMIC study palliative cohort
(European Association for the Study of the Liver) ILC 2018: The addition of SIRT to sorafenib in patients with advanced hepatocellular carcinoma was associated with no overall survival benefits compared with sorafenib alone, but may offer benefits in some subgroups of patients (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 13, 2018 Category: Cancer & Oncology Source Type: news

US study reports dramatic reduction in likelihood of liver transplantation in patients with hepatoce
(European Association for the Study of the Liver) ILC 2018: Although hepatocellular carcinoma is now the leading indication for liver transplantation in the USA, the probability of patients receiving a transplant has declined significantly in recent years. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 13, 2018 Category: International Medicine & Public Health Source Type: news